Pharm-Olam was selected by the US Department of Defense to run a mid-to late-stage trial of blockbuster autoimmune and inflammation drug adalimumab, knonw as AbbVie’s Humira.
Rankings by 
National Ranking
454th
in United StatesRegional Ranking
515th
in North America and CaribbeanGlobal Ranking
1246th
worldwide